For skin cancer, our multidisciplinary team includes dermatologists, dermatopathologists, surgical oncologists, radiation oncologists and medical oncologists. Our strong commitment to research led us to take an important role in the development of novel therapies including the checkpoint inhibitors which represent a breakthrough therapy for metastatic melanoma. Evidently, we routinely use molecular testing to allow our patients to benefit from targeted therapies in melanoma.
The Sarcoma group also comprises of a multidisciplinary team co-led by Dr. James Wittig, who co-authored a comprehensive book on Orthopedic Surgical Oncology Procedures. Our team has a strong focus on best practices in limb-sparring approaches and is working in concert with medical oncologists and radiation oncologists to improve the outcome for patients with sarcoma.